CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?

被引:0
作者
von Ahsen, Nicolas [1 ]
Binder, Claudia [2 ]
Brockmoeller, Juergen [3 ]
Oellerich, Michael [1 ]
机构
[1] Univ Gottingen, Klin Chem Abt, Univ Med Gottingen, D-37099 Gottingen, Germany
[2] Univ Gottingen, Abt Hamatol & Onkol, Univ Med Gottingen, D-37099 Gottingen, Germany
[3] Univ Gottingen, Klin Pharmakol Abt, Univ Med Gottingen, D-37099 Gottingen, Germany
来源
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE | 2009年 / 33卷 / 05期
关键词
breast cancer; CYP2D6; pharmacogenetics; tamoxifen; POSTMENOPAUSAL BREAST-CANCER; CYTOCHROME-P450; 2D6; CLINICAL-IMPLICATIONS; METABOLIZING-ENZYMES; ALLELE FREQUENCIES; GENETIC-VARIATION; GENOTYPE; SURVIVAL; VARIANTS; CYP2C19;
D O I
10.1515/JLM.2009.048
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The selective estrogen receptor modulator tamoxifen is approved for treatment of hormone receptor-positive breast cancer in pre- and postmenopausal patients. The main active metabolite of tamoxifen is endoxifen, which has high affinity towards the receptor and reaches high plasma concentrations. Endoxifen results from cytochrome P450 enzyme CYP2D6 action. CYP2D6 is subject to genetic polymorphism, with a prevalence of enzyme deficiency of approximately 7% in most European populations. Enzyme deficiency is reliably predicted by genotyping of known CYP2D6 deficiency alleles. Poor metabolizers (homozygote carriers of deficiency alleles) exhibit lower endoxifen plasma concentrations. Retrospective analyses of tamoxifen study data according to CYP2D6 genotypes reveal a poorer oncological outcome for subjects with deficiency alleles in most studies (level 3 evidence). Data from randomized controlled studies (level 1 evidence) on the use of CYP2D6 typing for tamoxifen therapy are lacking. However, CYP2D6 genotyping before initiating tamoxifen therapy and avoidance of tamoxifen in postmenopausal women with a CYP2D6 enzyme deficiency seem warranted. Prescribing information does not list CYP2D6 status as a contraindication for tamoxifen. Pharmacological supression of hot flashes by comedication with CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) must be avoided because such patients will become functional Poor metabolizers with lower endoxifen levels.
引用
收藏
页码:293 / 302
页数:10
相关论文
共 50 条
[41]   Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence [J].
Azoulay, Laurent ;
Dell'Aniello, Sophie ;
Huiart, Laetitia ;
du Fort, Guillaume Galbaud ;
Suissa, Samy .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (03) :695-703
[42]   CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response [J].
Pia P Wegman ;
Sten Wingren .
Breast Cancer Research, 7
[43]   Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping [J].
Binkhorst, Lisette ;
Mathijssen, Ron H. J. ;
Jager, Agnes ;
van Gelder, Teun .
CANCER TREATMENT REVIEWS, 2015, 41 (03) :289-299
[44]   Pharmacogenetic screening of the gene deletion and duplications of CYP2D6 [J].
Meijerman, Irma ;
Sanderson, Linda M. ;
Smits, Paul H. M. ;
Beijnen, Jos H. ;
Schellens, Jan H. M. .
DRUG METABOLISM REVIEWS, 2007, 39 (01) :45-60
[45]   Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio [J].
Lee, Clara Inkyung ;
Low, Siew Kee ;
Maldonado, Ricardo ;
Fox, Peter ;
Balakrishnar, Bavanthi ;
Coulter, Sally ;
de Bruijn, Peter ;
Koolen, Stijn L. W. ;
Gao, Bo ;
Lynch, Jodi ;
Zdenkowski, Nicholas ;
Hui, Rina ;
Liddle, Christopher ;
Mathijssen, Ron H. J. ;
Wilcken, Nicholas ;
Wong, Mark ;
Gurney, Howard .
BREAST, 2020, 54 :229-234
[46]   Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant [J].
Nadeeka Dimuthu Kumari Ranadeva ;
Nirmala Dushyanthi Sirisena ;
Tithila Kalum Wetthasinghe ;
Nafeesa Noordeen ;
Vajira Harshadeva Weerabaddana Dissanayake .
BMC Research Notes, 15
[47]   Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant [J].
Ranadeva, Nadeeka Dimuthu Kumari ;
Sirisena, Nirmala Dushyanthi ;
Wetthasinghe, Tithila Kalum ;
Noordeen, Nafeesa ;
Dissanayake, Vajira Harshadeva Weerabaddana .
BMC RESEARCH NOTES, 2022, 15 (01)
[48]   Pharmacogenetic-Based Clinical Scores: A Useful, Simple Tool to Predict Tamoxifen-Based CYP2D6 Phenotype? [J].
Fuhr, Uwe .
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04) :370-372
[49]   The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1 [J].
Teh, L. K. ;
Mohamed, N. I. ;
Salleh, M. Z. ;
Rohaizak, M. ;
Shahrun, N. S. ;
Saladina, J. J. ;
Shia, J. K. S. ;
Roslan, H. ;
Sood, S. ;
Rajoo, T. S. ;
Muniandy, S. P. ;
Henry, G. ;
Ngow, H. A. ;
Hla U, K. T. ;
Din, J. .
AAPS JOURNAL, 2012, 14 (01) :52-59
[50]   CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients [J].
Margolin, Sara ;
Lindh, Jonatan D. ;
Thoren, Linda ;
Xie, Hanjing ;
Koukel, Larissa ;
Dahl, Marja-Liisa ;
Eliasson, Erik .
PHARMACOGENOMICS, 2013, 14 (06) :613-622